RedHill Biopharma and Kukbo have signed an exclusive licence agreement for oral opaganib (ABC294640) to treat Covid-19 in South Korea.

A selective inhibitor of sphingosine kinase-2 (SK2), opaganib is claimed to have dual anti-inflammatory and antiviral activity. 

It is host-targeted and is intended to be effective against emerging variants of the SARS-CoV-2 virus. 

The oral therapy was found to have inhibition activity against variants of concern, including Delta. 

According to the deal, Kukbo will make an upfront payment of $1.5m to RedHill, which is also entitled to receive payments of up to $5.6m on meeting milestones.

RedHill will also receive low double-digit royalty payments on net product sales in South Korea. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, Kukbo will obtain the exclusive rights for the commercialisation of opaganib to treat Covid-19 in South Korea.

The latest agreement builds on strategic investment of up to $10m made by Kukbo in RedHill.

The collaboration with Kukbo also comprises a right of the first offer for late-stage clinical assets of RedHill in one or more of the territories of Japan, Indonesia, South Korea, Vietnam, Thailand and/or Malaysia. 

RedHill clinical assets in the late-stage include opaganib, RHB-107 (upamostat) and Talicia. 

Under the latest licence agreement, the right of the first offer has been expanded till October. 

Kukbo CEO Hyun Ha said: “Every day this month we are seeing an average of almost 2000 people hospitalised due to Covid-19 in South Korea and we desperately need medications that can effectively treat these patients. 

“With the data supporting opaganib for Covid-19 and the expanded partnership with RedHill, Kukbo is determined to work with local regulators with the aim of bringing opaganib to South Korean patients as soon as possible.”

In a Phase II/III clinical trial data, oral opaganib was found to enhance clearance of the viral RNA, offered a substantial decline in mortality when administered along with remdesivir and corticosteroids.